Sana Biotechnology Inc. $(SANA)$, a company focused on developing engineered cell therapies, has announced an upcoming presentation of updated six-month clinical results at the 85th Annual American Diabetes Association Scientific Sessions. The presentation will detail ongoing data from a first-in-human study of UP421, an allogeneic primary islet cell therapy modified with Sana's hypoimmune technology, designed for patients with type 1 diabetes. This study uniquely involves the transplantation of cells without the use of immunosuppression. The presentation is scheduled to occur during a joint ADA/International Pancreas & Islet Transplant Association symposium on June 23, 2025, in Chicago, IL, from 9:00 to 9:20 a.m. CT.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.